ArticleFrontiers in oncology2025
Radiotherapy is associated with improved survival in stage I-II gastric MALT lymphoma after failed or inadequate
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the impact of different first-line anti-tumor therapies on survival outcomes in patients with stage I-II gastric MALT lymphoma who failed or did not receive anti- Methods: Clinical data from 144 patients with anti- Results: Significant differences were observed among the three groups regarding staging, H. pylori status, prior anti-H. pylori therapy, elevated LDH, Ki67%, and CD20+ expression (p < 0.05). With a median follow-up of 59 months (IQR: 35-101 months), the radiotherapy-alone group (n = 56) demonstrated superior PFS (p = 0.001), and OS (p = 0.031) compared to the systemic therapy-alone group (n = 39). No significant differences in PFS (p = 0.358) or OS (p = 0.386) were observed between the radiotherapy-alone and combined therapy groups (n= 49). Stratification by radiotherapy dose (≤30 Gy, 31-35 Gy, 36-42 Gy) revealed no survival differences (p > 0.05). Univariate analysis identified low LDH, low MALT-IPI score, prior anti-H. pylori therapy, and radiotherapy (alone or combined) as protective factors against recurrence (p < 0.05). However, multivariate analysis confirmed only radiotherapy (alone or combined) as independent predictors of reduced recurrence (p < 0.05). Conclusion: Radiotherapy remains the highly effective option for anti-H. pylori therapy-failed or -naïve stage I-II gastric MALT lymphoma. Combined therapy provided no additional survival benefit over radiotherapy alone. Notably, prior (even failed) anti-H. pylori therapy may reduce recurrence risk, warranting further validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.